Directly from ACC 2024: SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH
An analysis of the DELIVER trial from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions is providing clinicians with new insight into the effects of SGLT2 inhibition across the range of left ventricular hypertrophy among patients with a left ventricular ejection fraction (LVEF) greater than 40%.
Presented by Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, results of the suited demonstrate use of dapagliflozin provided consistent benefit for event reductions and was well-tolerated in patients with heart failure across a range of left ventricular hypertrophy.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
